Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

EGF helps prevent inflammation-induced cancer

Epidermal growth factor (EGF) is a protein that normally regulates intestinal healing. However, biological therapies, like EGF, also may pose the risk of increasing the possibility of cancer. Philip Dubé, PhD, and Brent Polk, MD, both of the Saban Research Institute of Children's Hospital Los Angeles have demonstrated that in preclinical models, EGF encourages healing and provides powerful anti-inflammatory properties that prevent inflammation-induced cancer.

10 Jul 2012

The Jeffrey Epstein VI Foundation supports Genetic Initiative at CCFA

The Jeffrey Epstein VI Foundation, which actively supports science research, has given substantial support to the Crohn's and Colitis Foundation of America to continue its Genetic Initiative to find a cure for the diseases.

4 Jul 2012

CIHR and CH.I.L.D. create Canadian Children Inflammatory Bowel Disease Network

Dr. Grace McCarthy, Chairman of the Board of The Foundation for Children with Intestinal and Liver Disorders (CH.I.L.D), today announced an important new partnership with the Canadian Institutes of Health Research (CIHR) to fund the creation of the Canadian Children Inflammatory Bowel Disease Network: A Joint Partnership of CIHR and the CH.I.L.D. Foundation.

30 Jun 2012

Young inflammatory bowel disease patients have low bone mass

Children and adolescents with inflammatory bowel disease have significantly lower bone mineral density than their healthy peers, even after adjusting for pubertal delay, Finnish researchers report.

29 Jun 2012

Young inflammatory bowel disease patients have low bone mass

Children and adolescents with inflammatory bowel disease have significantly lower bone mineral density than their healthy peers, even after adjusting for pubertal delay, Finnish researchers report.

28 Jun 2012

Colectomy need in patients with severe ulcerative colitis drastically reduced by Kappaproct

InDex Pharmaceuticals today announced the publication of positive data from the Company's compassionate use program with its lead compound Kappaproct.

19 Jun 2012

Psoriasis link with autoimmune diseases underscored

Patients with psoriasis are nearly twice as likely to have an autoimmune disease as individuals without the condition, suggest study findings.

8 Jun 2012

Study suggests link between fungi and ulcerative colitis

Cedars-Sinai researchers say their examination of the fungi in the intestines suggests an important link between these microbes and inflammatory diseases such as ulcerative colitis.

7 Jun 2012

Pharmspective releases ‘Molecular Diagnostics Insights in Oncology’

Pharmspective, LLC today announced the release of its second syndicated report – Molecular Diagnostics Insights in Oncology. This new extensive survey of over 400 oncologists characterizes the emerging molecular diagnostics landscape and the role and influence of specific assays in clinical management and therapy selection.

31 May 2012

Bone age necessary to correctly interpret growth status in pediatric Crohn's disease

Measuring bone age should be a standard practice of care for pediatric patients with Crohn's disease, in order to properly interpret growth status and improve treatment, according to a new study from the UCSF Benioff Children's Hospital.

25 May 2012

Measuring bone age should be part of routine care for pediatric patients with Crohn's disease

25 May 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Santarus, Inc. today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the investigational drug UCERIS (budesonide) 6 mg tablets will be featured in four poster presentations at the Digestive Disease Week (DDW) Meeting being held at the San Diego Convention Center on May 19 - 22, 2012.

19 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

Imedex, Mechanisms in Medicine and Cornerstones launch new YouTube ‘You and IBD’

Cornerstones Health Inc., a nonprofit organization working to improve communication between patients with inflammatory bowel disease (IBD) and physicians who treat IBD, in collaboration with Imedex, LLC and Mechanisms in Medicine Inc., announced the launch of the new YouTube "You and IBD" - Animated IBD Patient Channel.

18 May 2012

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

11 May 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2012.

3 May 2012

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

30 Apr 2012